Close Menu

NEW YORK – Roche announced on Wednesday that its Elecsys Anti-p53 immunoassay for the quantitative detection of anti-p53 autoantibodies has received CE marking.

The assay is now available in markets that accept the designation.

The electrochemiluminescence test, which runs on Roche's line of Cobas e analyzers, can be used in conjunction with other diagnostic tests to help clinicians diagnose throat cancer, bowel cancer, and breast cancer, Roche said in a statement. It could also be used to monitor cancer cell remnants in a patient's body after treatment. 

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.